Published on
Jun 3, 2025
FDA-Approved SB16 Biosimilar Demonstrates Equivalence to Prolia
For countless women navigating postmenopausal osteoporosis (PMO), effective treatment often comes with a hefty price tag.1 New research shows that denosumab biosimilar SB16 is equivalent to the reference product, Prolia (denosumab), up to 12 months, which …
Source:
The Center for Biosimilars
-
Pending
